New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression

Core Insights - Artelo Biosciences, Inc. is focused on developing treatments for cancer, pain, and neuropsychiatric conditions through modulation of lipid-signaling pathways [1][5] - A recent publication highlights the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating mood and anxiety disorders, emphasizing the role of FABP5, FABP3, and FABP7 in neuroinflammatory signaling [2][3] Company Developments - Artelo's lead candidate, ART26.12, is a FABP5 inhibitor aimed at treating chemotherapy-induced peripheral neuropathy (CIPN) and is expected to report Phase 1 trial results in Q2 2025 [4] - The company has completed enrollment for a Phase 1 Single Ascending Dose study of ART26.12 with nearly 50 healthy volunteers, with data announcements anticipated this quarter [3][4] - Artelo's proprietary platform includes several backup and follow-on leads targeting FABP5 to elevate endogenous anandamide levels, which may provide anxiety-reducing and antidepressant effects without cognitive side effects [3][4] Research and Clinical Evidence - The peer-reviewed article co-authored by Doctor Steven Laviolette presents extensive preclinical evidence supporting the role of FABPs in the pathophysiology of anxiety and depression [2] - The findings suggest that inhibition of FABP5 can significantly elevate anandamide levels and modulate stress-related neurocircuits, indicating a promising avenue for neuropsychiatric treatment [3]